View Future GrowthDuality Biotherapeutics 과거 순이익 실적과거 기준 점검 0/6Duality Biotherapeutics 의 수입은 연평균 -303.2%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 16.5%의 비율로 증가해 왔습니다.핵심 정보-303.21%순이익 성장률-29.80%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률16.47%자기자본이익률-97.19%순이익률-130.43%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트공시 • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026모든 업데이트 보기Recent updates공시 • Jun 05Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026, at 09:30 China Standard Time. Location: board room, 11/f, building a, no. 868 yinghua road, pudong new area, shanghai China공시 • May 29Duality Biotherapeutics, Inc. (SEHK:9606) commences an Equity Buyback Plan for 8,803,626 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2025.Duality Biotherapeutics, Inc. (SEHK:9606) commences share repurchases on May 26, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 20, 2025. As per the mandate, the company is authorized to repurchase up to 8,803,626 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value and/or earnings per share for the company. The repurchases will be financed out of the funds legally available for such purpose in accordance with its Memorandum and Articles of Association and the laws of the Cayman Islands. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual general Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 20, 2025, the company had 88,036,264 shares in issue. On May 19, 2026, the company announced a share repurchase program. Under the program, the company will repurchase up to $40 million worth of its shares. The program will be funded from company's internal funds. The repurchased shares will be held as treasury shares.공시 • Apr 10DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast CancerDualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been accepted for review by the China National Medical Products Administration (NMPA). With the BLA filing, DualityBio is seeking approval for trastuzumab pamirtecan as second-line treatment for patients with unresectable or metastatic HER2-positive breast cancer. The application is based on positive interim results from the pivotal Phase III clinical trial (Study DB-1303-O-3001). The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed by the Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis. Trastuzumab pamirtecan ("T-Pam", also known as BNT323 or DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 which is being developed by BioNTech and DualityBio. Trastuzumab pamirtecan was built from DualityBio's proprietary Duality Immune Toxin Antibody Conjugates ("DITAC") platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells, making it a potential target for innovative cancer therapeutics. The candidate has exhibited antitumor activity in both HER2-positive and HER2-low tumor models as well as in several solid tumor indications, including patients with breast and endometrial cancers, as well as other advanced solid tumors. Preclinical data and preliminary clinical data for trastuzumab pamirtecan indicate its potential to target HER2 receptors on solid tumors irrespective of expression level with a manageable safety profile and a potentially expanded therapeutic window. Trastuzumab pamirtecan is currently being evaluated in multiple solid tumor types and innovative treatment combinations, including two global pivotal clinical trials in first-line HER2-low, hormone receptor positive ("HR+") metastatic breast cancer (DYNASTY-Breast02; NCT06018337) and second-line endometrial cancer (BNT323-01; NCT06340568), a novel-novel combination Phase 1/2 clinical trial (BNT323-03; NCT06827236) evaluating trastuzumab pamirtecan in combination with pumitamig in HR-positive or –negative, HER2-low, -ultra-low, or -null advanced/metastatic breast cancer and a Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (NCT06340568).공시 • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026매출 및 비용 세부 내역Duality Biotherapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:DUTB.F 매출, 비용 및 순이익 (CNY Millions)날짜매출순이익일반관리비연구개발비30 Jun 252,170-2,83121180931 Mar 252,056-1,94118581231 Dec 241,941-1,05015981531 Dec 231,787-35863559양질의 수익: DUTB.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: DUTB.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 DUTB.F의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 DUTB.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: DUTB.F은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: DUTB.F는 현재 수익성이 없으므로 자본 수익률이 음수(-97.19%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/01/17 17:24종가2025/10/20 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Duality Biotherapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Qianlan ZhuCGS InternationalLily WangCGS InternationalLily WangChina Galaxy International Securities (Hong Kong)7명의 분석가 더 보기
공시 • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026
공시 • Jun 05Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026, at 09:30 China Standard Time. Location: board room, 11/f, building a, no. 868 yinghua road, pudong new area, shanghai China
공시 • May 29Duality Biotherapeutics, Inc. (SEHK:9606) commences an Equity Buyback Plan for 8,803,626 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2025.Duality Biotherapeutics, Inc. (SEHK:9606) commences share repurchases on May 26, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 20, 2025. As per the mandate, the company is authorized to repurchase up to 8,803,626 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value and/or earnings per share for the company. The repurchases will be financed out of the funds legally available for such purpose in accordance with its Memorandum and Articles of Association and the laws of the Cayman Islands. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual general Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 20, 2025, the company had 88,036,264 shares in issue. On May 19, 2026, the company announced a share repurchase program. Under the program, the company will repurchase up to $40 million worth of its shares. The program will be funded from company's internal funds. The repurchased shares will be held as treasury shares.
공시 • Apr 10DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast CancerDualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been accepted for review by the China National Medical Products Administration (NMPA). With the BLA filing, DualityBio is seeking approval for trastuzumab pamirtecan as second-line treatment for patients with unresectable or metastatic HER2-positive breast cancer. The application is based on positive interim results from the pivotal Phase III clinical trial (Study DB-1303-O-3001). The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed by the Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis. Trastuzumab pamirtecan ("T-Pam", also known as BNT323 or DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 which is being developed by BioNTech and DualityBio. Trastuzumab pamirtecan was built from DualityBio's proprietary Duality Immune Toxin Antibody Conjugates ("DITAC") platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells, making it a potential target for innovative cancer therapeutics. The candidate has exhibited antitumor activity in both HER2-positive and HER2-low tumor models as well as in several solid tumor indications, including patients with breast and endometrial cancers, as well as other advanced solid tumors. Preclinical data and preliminary clinical data for trastuzumab pamirtecan indicate its potential to target HER2 receptors on solid tumors irrespective of expression level with a manageable safety profile and a potentially expanded therapeutic window. Trastuzumab pamirtecan is currently being evaluated in multiple solid tumor types and innovative treatment combinations, including two global pivotal clinical trials in first-line HER2-low, hormone receptor positive ("HR+") metastatic breast cancer (DYNASTY-Breast02; NCT06018337) and second-line endometrial cancer (BNT323-01; NCT06340568), a novel-novel combination Phase 1/2 clinical trial (BNT323-03; NCT06827236) evaluating trastuzumab pamirtecan in combination with pumitamig in HR-positive or –negative, HER2-low, -ultra-low, or -null advanced/metastatic breast cancer and a Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (NCT06340568).
공시 • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026